Sun Chemical has launched SunCure EcoPlast, a press-ready dry UV offset ink range designed for sustainable plastic cup decoration.

Q2 2020 Highlights *Net Sales were $1,611.0 million versus $1,552.8 million in the prior year period. *Net Income was $52.1 million versus $63.8 million in the prior year period. *Net organic sales increased 1.5% in Q2 and 3% in the first half of 2020 versus the prior year periods. *Continue to operate safely and effectively; investing in multiple protocols focused on the well-being of employees and serving customers globally. *Successfully closed the 70,000 ton White Pigeon, Michigan Coated Recycled Board (CRB) mill and shut down the 120,000 ton West Monroe, Louisiana PM1 containerboard machine. *Repurchased $38.0 million in common shares during the quarter; delivered $64.9 million to stakeholders in share repurchases, dividends and partnership distributions.

Sonoco ThermoSafe has launched a new range of reusable, universal solutions for the pharmaceutical and biologics markets. ChillTech® is a pre-qualified range of 2°C to 8°C PCM systems providing exceptional temperature control from 2 days up to 6 days for payloads from 4L to 40L. ChillTech® utilizes Sonoco ThermoSafe's patented Zero Bench-Time® technology, where systems can be packed-out straight from the freezer, saving customers space, time and money. Similar shippers on the market are qualified for just 4-days and typically use high-value components, which translate into higher costs for customers. These shippers also typically need time outside of the freezer prior to packing out, making Sonoco ThermoSafe's Zero Bench-Time technology a real benefit. Each ChillTech solution has the same pack-out configuration and is used year-round, regardless of season. In addition, following Sonoco ThermoSafe's philosophy to Embrace Simple®: simply change the outer insulated shipper to switch shipment duration from 48 hours to 96 hours to 144 hours. Click Read More below for additional details.

First Quarter 2022 Summary *Reported sales grew 9% and core sales (excluding currency effects and acquisitions) grew 13% with double-digit core growth in each segment *Pharma segment posted sales growth in all markets including the prescription drug division as demand for allergic rhinitis and asthma devices began to recover *Reported earnings per share of $0.93 compared to $1.24 in the prior year; prior year results included an effective tax rate of 17% and an unrealized gain of $17 million related to changes in the fair value of an equity investment